---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-009476"
form_type: "8-K"
ticker: "MDGL"
cik: "0001157601"
company_name: "MADRIGAL PHARMACEUTICALS, INC."
filed_at: "2026-02-19T23:59:59+00:00"
generated_at: "2026-05-16T01:39:32.743818+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Madrigal reports Q4 Rezdiffra sales $321M, FY $958M; pipeline expands with siRNA and GLP-1 deals

## Summary
- Q4 2025 Rezdiffra net sales $321.1M; full-year net sales $958.4M, vs $180.1M in 2024.
- More than 36,250 patients on Rezdiffra as of year-end 2025.
- Cash, equivalents and marketable securities $988.6M as of Dec. 31, 2025.
- Licensed global rights to six pre-clinical siRNA programs and oral GLP-1 (MGL-2086) to combine with Rezdiffra.
- Secured Orange Book listed Rezdiffra patent with protection into 2045; also closed $500M credit facility.

## SEC filing metadata
- accession: 0001628280-26-009476
- form_type: 8-K
- ticker: MDGL
- cik: 0001157601
- company_name: MADRIGAL PHARMACEUTICALS, INC.
- filed_at: 2026-02-19T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1157601/000162828026009476/0001628280-26-009476-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1157601/000162828026009476/mdgl-20260219.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-009476
- JSON: https://secwatch.observer/filing/0001628280-26-009476.json
- Plain text: https://secwatch.observer/filing/0001628280-26-009476.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.